Perimenopause changes where the body stores fat — pushing it toward the midsection — and GLP-1 medications can take a meaningful share of weight loss from muscle unless muscle is actively protected, so the right approach is built around body composition rather than the scale. Across GLP-1 studies, roughly 25–40% of the weight lost has come from lean mass when protein and resistance training weren’t deliberately in place (2022 meta-analysis, via ACE). For a woman in perimenopause — already facing a shift toward abdominal fat and a natural decline in muscle — that combination is exactly what a measured plan is designed to manage.
This is a practical guide, not a pitch. It covers why perimenopause changes the math, what GLP-1s do and don’t do to muscle, where a peptide like tesamorelin fits (and where it doesn’t), and how to judge whether any of it is working. The theme throughout: measure, don’t assume.
Why does perimenopause change where you gain weight?
The perimenopausal shift isn’t only about total pounds. As estrogen falls and fluctuates, fat storage tends to move toward the abdomen — including visceral fat, the metabolically active fat around the organs — and insulin sensitivity and muscle mass can decline at the same time. The result many women describe is familiar: the scale may barely move, but the middle changes and energy drops. That is a metabolic and hormonal shift, not a failure of willpower, and it responds better to a monitored, structural approach than to another round of restriction.
Because this is happening on top of the fatigue most women in perimenopause report, it’s worth ruling out the other common drivers of low energy and stalled progress first. Our companion piece on perimenopause exhaustion and “normal” labs covers that baseline.
What do GLP-1s actually do to muscle?
GLP-1 receptor agonists (semaglutide, tirzepatide and others) are effective at reducing weight. Like nearly all rapid weight loss, some of what comes off is lean mass, not just fat. The most-cited figure is from a 2022 meta-analysis: about 25–40% of the weight lost on GLP-1s came from lean mass in studies where muscle wasn’t actively defended (ACE summary). More recent analyses argue the picture is often more favorable — fat loss generally exceeds muscle loss in both absolute and relative terms — but the honest read is that muscle can be lost, and midlife women, who are already fighting age-related muscle decline, have the most to protect.
The key point is that the drug doesn’t determine the ratio on its own. What you do alongside it does.
What actually protects muscle on a GLP-1?
Two levers do most of the work, and neither is a medication:
Protein. Appetite suppression is the mechanism GLP-1s use, which makes it easy to under-eat protein specifically. Hitting a deliberate daily protein target is the single most important dietary lever for holding lean mass during weight loss.
Resistance training. Progressive strength work is the signal that tells the body to keep muscle while it sheds fat. Without it, the body has little reason to preserve tissue it isn’t using.
Everything else — adequate sleep, not cutting calories more aggressively than needed, and re-checking as you go — supports those two. We go deeper on the mechanics in how to prevent muscle loss on a GLP-1 and protecting muscle on a GLP-1.
Where does a peptide like tesamorelin fit?
Tesamorelin is a GHRH analog that is FDA-approved to reduce excess visceral fat in HIV-associated lipodystrophy (manufacturer/clinical background). Because perimenopausal weight change is disproportionately visceral, it comes up in longevity-clinic conversations — but two honest caveats belong up front. First, use for general midlife visceral fat is off-label and rests on earlier-stage evidence than its approved indication. Second, it is not a replacement for a GLP-1, for protein, or for training; at most it’s an adjunct considered within a clinical relationship. Our explainer on what tesamorelin is lays out the mechanism and the evidence in full.
The takeaway is not “add a peptide.” It’s that visceral fat is a specific target with specific tools, and any of them belongs under supervision and measurement — never a self-directed experiment.
How should you actually measure progress?
Here is the reframe that changes decisions: the scale can’t tell fat from muscle. A pound lost is not automatically a good pound. The reliable read is body composition plus strength plus baseline labs, tracked over time.
| What to track | Why it matters | Cadence |
|---|---|---|
| Body composition (DEXA or bioimpedance) | Separates fat loss from muscle loss — the thing the scale hides | Baseline, then ~every 3 months |
| Strength (key lifts / functional benchmarks) | A direct, honest proxy for whether lean mass is holding | Ongoing |
| Baseline labs (metabolic, thyroid, iron, hormones as indicated) | Screens the other drivers and sets your personal baseline | Baseline, re-test ~90 days |
| Waist / visceral trend | Tracks the perimenopausal shift specifically | Periodic |
If fat is coming down while lean mass and strength hold, the protocol is working — regardless of what the scale says on a given morning. If lean mass is falling with the fat, that’s the signal to adjust protein, training, or the medication plan with your clinician. A medically supervised GLP-1 program makes that kind of adjustment possible, pairing the prescription with body-composition tracking and a clinician who can change course.
GLP-1 medications and peptides such as tesamorelin are prescribed and monitored within a licensed clinical relationship, based on your own history and labs. Compounded medications, where used, are prepared by a state-licensed, FDA-regulated compounding pharmacy and are not FDA-approved as finished products. Off-label use is described honestly as such. This is educational information, not medical advice or a promise of results.
Perimenopause, GLP-1s, and muscle FAQ
Why is it harder to lose weight during perimenopause? Falling and fluctuating estrogen in perimenopause tends to shift fat storage toward the abdomen and can reduce insulin sensitivity and muscle mass, so the same habits produce different results. It reflects a metabolic change, not a lack of discipline — which is why a measured, monitored approach works better than restriction alone.
Do GLP-1s cause muscle loss? GLP-1 weight loss includes some lean-mass loss like most rapid weight loss. A 2022 meta-analysis found roughly 25–40% of the weight lost on GLP-1 receptor agonists came from lean mass when muscle wasn’t actively protected. Adequate protein and resistance training substantially change that ratio, which is why monitoring body composition matters.
Should perimenopausal women avoid GLP-1s because of muscle loss? Not necessarily. The concern is a reason to use them carefully — with enough protein, resistance training, and body-composition tracking — not automatically a reason to avoid them. That decision belongs in a clinical relationship that reviews your labs, goals, and history.
What is tesamorelin and how does it relate to visceral fat? Tesamorelin is a GHRH analog that is FDA-approved to reduce excess visceral fat in HIV-associated lipodystrophy. Its use for general midlife visceral fat is off-label and earlier-stage; it is prescribed and monitored within a clinical relationship, not a substitute for a GLP-1 or for training and protein.
How do I know if I’m losing fat or muscle? The scale can’t tell you. Body-composition measurement (such as a DEXA scan or bioimpedance) plus strength and baseline labs, re-checked over time, shows whether you’re holding lean mass while fat comes down. That trend is the real read on whether a protocol is working.
A measured plan starts with knowing your baseline — body composition, not just weight. Find Your Treatment →
Sources
- ACE — GLP-1s and Lean Mass: What the Research Shows (summarizing a 2022 meta-analysis on lean-mass share of GLP-1 weight loss): https://www.acefitness.org/continuing-education/certified/june-2025/8892/glp-1s-and-lean-mass-what-the-research-shows/
- Cell Reports Medicine — Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00082-0
- Tesamorelin efficacy and safety in people with HIV (clinical background for the FDA-approved indication): https://pmc.ncbi.nlm.nih.gov/articles/PMC11365754/